Abstract
ObjectivesThe emergence of targeted therapy is changing rheumatoid arthritis (RA) management, but real-world data remain limited. This study aimed to describe real-world RA treatment patterns using data from a French national claims database.MethodsThis longitudinal study used the French Permanent Representative Sample (Echantillon Généraliste des Bénéficiaires) claims database. Patients with RA were identified between 2013 and 2017, with treatment patterns, persistence and adherence described.ResultsThe study population included 2553 patients with RA. Disease-modifying antirheumatic drugs (DMARDs) were prescribed for 1512 (59.2%) patients, of whom 721 (47.6%) did not require discontinuation or treatment switch. There were 377 (24.9%) treatment discontinuations and 114 patients (7.5%) switched to a targeted DMARD (biological and synthetic (Janus kinase inhibitor) DMARDs). Among the 2315 patients with RA in 2017, almost half (n=1102, 47.6%) were not treated with a DMARD. Most (85.7%) received symptomatic treatment (analgesics (81.0%), steroids (49.2%), non-steroidal anti-inflammatory drugs (39.5%)). Of the 1142 treatment initiations identified, 713 (62.4%) were conventional synthetic DMARDs (csDMARDs), with methotrexate being the most frequent (n=553, 48.45%). One-year persistence rates varied between 55.9% (49.2–62.0%) for tumour necrosis factor inhibitors, and 63.4% (59.6–67.0%) for csDMARDs. Treatment adherence, assessed through medication possession ratio, varied between 71.9% and 90.8%, with ≥80% being the adherence cut-off. Almost half of DMARD initiations were associated with long-term (>6 months), high-dose oral steroid use (~7 mg/day prednisone equivalent).ConclusionDespite a diverse therapeutic arsenal, there remains a medical need that is not covered by current RA management, which is frequently compensated for by overprescription of steroids.
Subject
Immunology,Immunology and Allergy,Rheumatology
Reference46 articles.
1. Rheumatoid arthritis
2. The global prevalence of rheumatoid arthritis: a meta-analysis based on a systematic review;Almutairi;Rheumatol Int,2021
3. Prevalence of specific types of arthritis and other rheumatic conditions in the ambulatory health care system in the United States, 2001–2005;Sacks;Arthritis Care Res (Hoboken),2010
4. Haute Autorité de Santé . Évaluation médico-économique des traitements de fond biologiques dans la prise en charge de la polyarthrite rhumatoïde [Internet]. n.d. Available: https://www.has-sante.fr/jcms/c_2580906/fr/evaluation-medico-economique-des-traitements-de-fond-biologiques-dans-la-prise-en-charge-de-la-polyarthrite-rhumatoide